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Background:	 Acute	 thrombotic	 syndromes	 lead	 to	 atherosclerotic	 plaque	 rupture	










GPVI	 and	αIIbβ3	are	 sufficient	 to	 significantly	 inhibit	washed	platelet	 aggregation	
and	decrease	thrombus	formation	on	fibrillar	collagen.
Conclusions:	Our	data	demonstrate	a	role	for	MMP-	13	in	the	inhibition	of	both	plate-
let	 aggregation	and	 thrombus	 formation	 in	whole	 flowing	blood,	 and	may	provide	
new	avenues	of	research	into	the	mechanisms	underlying	the	subtle	role	of	MMP-	13	
in	atherothrombotic	pathologies.





























Our	work	 identifies	potential	 roles	 for	MMP-	13	 in	modulating	 the	
recruitment	or	activation	of	platelets	in	thrombotic	pathologies.
2  | METHODS
2.1 | MMP- 13 expression, purification and activation
ProMMP-	13	 and	 its	 MMP-	13	 catalytic	 (CAT,	 249-	451)	 domain	
were	 expressed,	 purified,	 activated,	 and	 dialysed	 as	 previously	 de-
scribed.14–16	 The	 structurally	 homologous	 but	 catalytically	 inactive	
proMMP-	13(E204A)	was	a	kind	gift	from	Dr.	R.	Visse	(Kennedy	Institute	
of	 Rheumatology	 Division,	 Imperial	 College	 London,	 London,	
UK).	 GST-	Hemopexin	 (HPX)	 domain	 (264-	471)	 was	 expressed	 in	
E. coli	 using	 the	 pGEX-	2T	 expression	 vector,	 the	 forward	 primer	
TCCGCGTGGATCCCTCTATGGTCCAGGAGATGAA	 and	 the	 reverse	
primer	GCAA-	ATTCCATTTTGTGGTGTTGAAGAATTCAT,	which	contain	
BamHI	and	EcoRI	restriction	sites	respectively,	as	previously	described.16
2.2 | Washed platelet preparation and platelet 
adhesion assays
Plates	were	 coated	with	 10	μg/ml	MMP-	13	 variants	 in	 Tris	 buff-
ered	 saline	 (TBS)	 for	1	h	at	24°C.	Plates	were	 then	blocked	with	
5%	 BSA	 in	 TBS	 for	 20	minutes	 at	 24°C	 and	 washed	 with	 TBS	 
prior	 to	 the	 addition	 of	 washed	 platelets.	 Platelets	 were	 puri-
fied	 and	 adhesion	 assays	 conducted	 as	 previously	 described.17,18 
Glanzmann	 thrombasthenic	 blood	 was	 kindly	 provided	 by	




GFOGER	 (GPC[GPP]5-	GFOGER-	[GPP]5-	GPC)	 and	 GPVI-	binding	
peptide	 CRP-XL	 (GCO-[GPO]10-GCOG);	 cross-	linked	 where	 ap-
propriate	 and	 the	 inert	 GPP10	 (GPC-	[GPP]10-	GPC)	 were	 gener-
ated	 as	 previously	 described7	 along	 with	 the	 anti–GPVI	 scFvs	
10B12	 and	 1C3	 and	 the	 non-	GPVI-	binding	 scFv	 2D419–23 which 
















Austria),	 thrombin	 activating	 peptide	 (TRAP;	 500	μmol	L−1;	 Sigma,	
UK)	 calcium	 ionophore	 A23187	 (100	μmol	L−1;	 Sigma	 UK)	 or	 HBS	
(negative	 control)	 added.	Alexa	 488	 conjugated	 anti-	mouse	 (30	μg/
ml	 final	 concentration;	 Jackson	 Immuno	 Research,	 Ely,	 UK)	 was	
then	added	and	after	10	minutes	at	24°C	 the	volume	was	made	up	
to 500 μl	with	 isotonic	 solution.	After	 30	minutes	 fluorescence	was	
measured	using	an	Accuri	C6	flow	cytometer	(BD	Biosciences,	Oxford,	
UK).	 In	 inhibition	experiments,	whole	blood	was	pre-	incubated	with	
proMMP-	13(E204A),	 GR144053	 (20	μmol	L−1)	 or	 10B12	 (10	μg/ml)	
for	20	minutes	prior	to	the	addition	of	CRP-	XL.
2.4 | Solid phase adhesion assays
Recombinant human αIIbβ3	and	GPVI	monomer	were	obtained	from	
R&D	 Systems	 (Abingdon,	 Oxford,	 UK).	 Recombinant	 extracellular	



























2.6 | Cleavage of platelet receptors and their 
substrates by MMP- 13
Recombinant	 human	 (rh)GPVI,	 purified	 αIIbβ3 (100 μg/mL,	 R&D	
Systems)	 and	 human	 fibrinogen	 type	 I	 (1	mg/mL)	 were	 incubated	




2.7 | In vitro sheddase activity assays
Dialysed	MMP-	13	at	a	 final	 concentration	of	130	nmol	L–1 was in-
cubated	 with	 washed	 platelets	 for	 60	minutes	 at	 37°C.	 Positive	
controls	for	shedding	included	thrombin	(1	U/mL,	Sigma,	UK)	com-
bined	with	fibrous	type	I	collagen	(1	mg/mL),	the	calcium	ionophore	
A23187	 (1	μg/mL).	 The	platelets	were	 then	pelleted	 at	1500	g	 for	




2.8 | Electrophoresis and Western blotting
Protein	samples	in	reducing	sample	buffer	were	boiled	for	5	minutes	
and	applied	to	4-	12%	NuPage	Gels	and	separated	by	electrophore-
sis	 using	 the	Xcell	 SureLock	 system	 (Invitrogen,	Paisley,	UK)	 under	
reducing	conditions.	Proteins	were	 then	 transferred	on	 to	nitrocel-
lulose	membrane	 (Millipore,	Bedford,	UK)	at	40	V	overnight	at	4°C	








incubated	with	anti-	GPVI,	αIIbβ3 or α2β1 
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TBST,	 the	membrane	was	 incubated	with	HRP	conjugated	 second-
ary	 antibody	 (1:10000	 dilution/TBST)	 for	 1	h	 at	 24°C.	 The	 PVDF	
was	developed	using	a	chemiluminescent	substrate	(GE	Healthcare,	
Amersham,	Bucks,	UK).
2.9 | Whole blood perfusion experiments





Adhesion	 assays	 were	 performed	 in	 the	 presence	 of	 2	mmol	L−1 
EDTA	 or	 Mg2+	 to	 ablate	 or	 support	 integrin-	mediated	 adhesion.	
Platelet	 adhesion	 to	 MMP-	13	 preparations	 was	 significantly	 re-
duced,	 but	 not	 abolished,	 by	 EDTA,	 suggesting	 both	 integrin-	
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1C3	 binding	 requires	 both	GPVI	 Ig	 domains	 and	 is	 thought	 to	 re-
duce	platelet	activation	by	inhibiting	receptor	clustering;	its	epitope	











provided	 further	evidence	 that	MMP-	13	 interacts	with	both	GPVI	
and αIIbβ3;	like	GR144053	and	10B12,	MMP-	13	can	compete	αIIbβ3 
off	immobilized	fibrinogen	and	GPVI	off	CRP	(IC50	150	ng/mL	and	
~10	ng/mL	 respectively;	 Figures	2A[i-	iv]).	 Solid	 phase	 binding	 as-
says	 to	 coated	 isolated	 receptors	 revealed	 that	MMP-	13	was	 able	







αIIbβ3	on	healthy	platelets	 resulted	 in	 the	 same	adhesion	 level	 as	





Whilst	it	was	able	to	cleave	the	recombinant	αIIbβ3 β- chain and 
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MMP-	13	was	unable	to	either	cause	or	mediate	shedding	of	either	
receptor	in	situ	(Figure	3B).
Pre-	incubation	 of	 washed	 platelets	 for	 1	h	 with	 80	nmol	L−1 
MMP-	13(E204A)	significantly	reduced	platelet	aggregation	to	a	se-
ries	of	agonists,	and	for	the	mid-	range	dose	of	each,	analyzed	using	







antibody	 was	 observed	 following	 the	 incubation	 of	 whole	 blood	
with	 pro-	MMP-	13(E204A)	 or	 MMP-	13,	 whereas	 clear	 expression	













platelet	surface	coverage	(P < .05),	mean	thrombus	height	(P < .01),	
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and	 ZV50 (P < .05),	 using	 one-	way	 anova	 and	 Holm	 multiple	 com-
parison	 test;	 Figure	6A(i-	iii).	 ZV50	 is	 the	 height	within	 a	 Z-	stack	 at	
which thrombus volume = 50% and describes the activation state 
of	adhered	platelets	in	flowing	human	blood.25	Data	obtained	using	













We	have	previously	 shown	 that	degradation	by	MMP-	13	has	 the	
potential	 to	modulate	 platelet	 adhesion	 to	 collagen.17	MMPs	 are	
zymogens;	 proteolysis	 is	 required	 to	 expose	 their	 catalytic	 site.	
Here	we	show	that	surprisingly,	all	forms	of	MMP-	13,	pro-	and	ac-
tive	wild	type	enzyme	as	well	as	their	catalytically	inactive	mutant	
counterparts,	were	 able	 to	 support	 a	 high	 level	 of	 platelet	 adhe-














null	 platelets	 to	 MMP-	13	 was	 significantly	 reduced.	 Following	
pre-	incubation	 of	 washed	 platelets	 with	 MMP-	13,	 neither	 GPVI	












C6	flow	cytometer	(BD	Biosciences,	Oxford,	UK).	Data	represent	mean	A450	±	SE	of	three	separate	donors.	**P < .005; (one- way anova and 
Holm	multiple	comparison	test)
P- selectin expression following agonist addition(A) (B) P- selectin expression following inhibitor
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to	cleave	and	thus	activate	PAR-	1	on	cardiac	cells.30 This has not 
been	demonstrated	on	platelets,	and	may	result	in	platelet	activa-
tion concomitant with αIIbβ3	 inhibition,	however	 in	 this	case	 the	











solution-	phase	CRP-	XL	 and	 so	 alter	 platelet	 secretion.	 In	 this	 re-
spect,	it	behaves	much	like	the	αIIbβ3	antagonist,	GR144053,	and	
it	would	 appear	 therefore	 that	 the	 inhibitory	 effects	 of	MMP-	13	
in	 solution	 are	 mediated	 predominantly	 through	 αIIbβ3.	 At	 con-
centrations	comparable	to	those	reached	in	stroke	patient	plasma	
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to	 interfere	 with	 the	 progression	 of	 plaque	 rupture,	 subsequent	
thrombosis	 and	 its	 associated	 pathologies	 including	 stroke,	 reper-
fusion	 injury,	 and	 hemorrhagic	 transformation.	 Indeed,	 these	 pro-
cesses	are	associated	with	an	upregulation	of	MMP	activity.2,31,36 In 
mice,	MMP-	13	is	the	key	mediator	of	collagen	degradation	in	ather-
oma	and	confers	 instability	onto	 the	vulnerability	plaque	cap.37–39 
Disruption	of	the	blood	brain	barrier	 (BBB)	by	MMPs	is	associated	
with	 hemorrhagic	 transformation	 following	 ischemic	 stroke,36,40,41 
whilst	MMPs	 -	9	 and	 -	13	 are	 implicated	 in	 the	 early	 pathology	 of	
stroke	progression,	and	plasma	MMP-	13	levels	correlate	with	lesion	
volume.2,31	In	addition,	the	platelet	collagen	receptor	GPVI	has	been	
identified	in	models	of	models	of	reperfusion	injury,42 is associated 
with	 increased	 risk	 of	 stroke	 development,	 and	 is	 also	 seen	 after	
ischemic	stroke.43
Here	we	demonstrate	that	MMP-	13	can	exert	an	antithrombotic	
effect;	 inhibiting	 platelet	 aggregation	 and	 thrombus	 formation	 in	
flowing	whole	blood.	It	may	be	that	this	metalloproteinase	has	mul-
tiple	roles	in	the	pathology	of	ischemic	stroke;	firstly	by	undermin-
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